Skip to main content

Table 1 Study characteristics

From: The role of total cell-free DNA in predicting outcomes among trauma patients in the intensive care unit: a systematic review

Author

Method

Patients, n

Age, years

Sex male, n (%)

Time of measurement

Severity score (n) [range]

DNA measurement scorea

Nonspecific trauma

 Ren et al. (2013) [37]

Cohort study

56

38 ± 14

47 (83.9%)

1–6 h, 24–36 h, 60–90 h

ISS, minor: 4.8 ± 1.7 (16) ISS, moderate: 11.1 ± 1.9 (19) ISS, severe: 33.7 ± 20.0 (21)

4

 Margraf et al. (2008) [15]

Prospective cohort

37

45 ± 21.3

24 (64.9%)

ICU admission, 1–10 days

ISS, 31.6 ± 11 [16–50]

5

 Lo et al. (2000) [14]

Retrospective study

84

  

ICU admission

ISS, minor/moderate: <16 (47) ISS, major: ≥16 (37)

3

 Wijeratne et al. (2004) [39]

Cohort study

96

63 (25–85)

69 (73.4%)

ICU admission

?

5

 Lam et al. (2003) [29]

Observational study

25

38

24 (63.2%)

Study 1: ICU admission, every 20 min for 180 min Study 2: ICU admission every day for 28 days

ISS, minor: <9 (4) ISS, moderate: 8–15 (10) ISS, severe:16–24 (7) ISS, very severe: >25 (4)

3

 McIlroy et al. (2014) [43]

Prospective cohort and healthy controls

35

38 (29–48)

25 (71.4%)

Preoperative, immediately postoperative, 7 h postoperative, 24 h postoperative, 3 days postoperative, 5 days postoperative

Median ISS: 14 [9-22]

4

 Yamanouchi et al. (2013) [34]

Prospective study

37

56 (35–70)

26 (70.2%)

ICU admission, days 1–2 and day 4

AIS >3 SOFA score (day 1) 2 [2-4] APACHE II score (day 1) 11 [6-15]

2

 Lam et al. (2004) [36]

Prospective cohort and healthy controls

38

NA

NA

ICU admission

ISS <16 (28) ISS >16 (10)

4

 Gu et al. (2013) [35]

Prospective cohort and healthy controls

86

45.5 (28.75–57.25)

61 (70.1%)

ICU admission

SIRS absent ISS 14 [9.75-18.25] (50) SIRS present ISS 22 [18-29] (36) SIRS present APACHE II 11.5 [8-16] SIRS absent APACHE II 9 [6-11]

4

Traumatic brain injury

 Macher et al. (2012) [30]

Prospective cohort and healthy controls

65

38.18 ± 2.02

56 (86%)

ICU admission, 24 h, 48 h, 72 h and 96 h postoperative

GCS: 7 [3-9] ISS: 36 [9-75] APACHE II: 19 [5-34]

2

 Shaked et al. (2014) [31]

Selected patients from a cohort

28

49 (18–91)

23 (82.1%)

ICU admission

GCS ≥14 (14) GCS ≤13 (14) AIS 0–2 (10) AIS 3–5 (18)

 

 Yurgel et al. (2007) [32]

Selected patients from a cohort

41

34 (18–64)

41 (100%)

Study entry, 24 h later

GCS survivors: 6.5 GCS nonsurvivors: 5 APACHE II survivors: 12.5 APACHE II nonsurvivors: 18.3

2

 Filho et al. (2014) [33]

Prospective cohort and healthy controls

188

34.8 (13.9)

165 (88%)

ICU admission

GCS survivors: 6.3 GCS nonsurvivors: 5.2

4

 Wang et al. (2014) [16]

Prospective cohort

88

36 (20–53.75)

55 (62.5%)

ICU admission, 4 days, 7 days

GCS: 15 [13-15] ISS: 16 [11-20]

4

  1. Values are given as mean ± SD or median (interquartile range) unless indicated otherwise
  2. AIS abbreviated injury scale, APACHE Acute Physiology and Chronic Health Evaluation, GCS Glasgow Coma Scale, ICU intensive care unit, ISS Injury Severity Score, NA not available, SOFA Sepsis-related Organ Failure Assessment, SIRS systemic inflammatory response syndrome
  3. aEvery study was assessed for cfDNA sampling and analysis: 1 point was given if circulating DNA was analyzed in plasma; 1 point was given if blood was collected in either an EDTA tube or cell-free DNA tube; 1 point was given if blood was processed before 4 h; 1 point was given if blood was centrifuged one or more times; 1 point was given if blood was frozen at –80 °C or –20 °C depending on whether cfDNA analysis was based on specific sequence or cfDNA quantification, respectively